A Systematic Review on the Role of Digital Twin Technology in Enhancing Product Life Cycle Management in the Pharmaceutical Industry

Managing a pharmaceutical product from its conceptual origin to its eventual discontinuation has never been a straightforward endeavor. The sheer complexity involved spanning laboratory research, formulation testing, regulatory submissions, large-scale manufacturing, global distribution, and pharmacovigilance demands an integrated, data-coherent approach that traditional product life cycle management (PLM) systems have often struggled to fully provide. Siloed databases, delayed feedback loops, and reactive rather than predictive quality management have historically undermined efficiency in pharmaceutical development and production. It is within this context that digital twin technology has gained considerable attention. Originally developed within aerospace and advanced manufacturing, digital twins are now being explored and adopted across healthcare and pharmaceutical sectors as a means of bridging the gap between physical operations and real-time data intelligence.^[1] A digital twin — in its most functional form — is a continuously updated virtual model of a product, process, or system that mirrors its physical counterpart throughout its operational life. When integrated into a pharmaceutical PLM framework, this technology offers the prospect of predicting equipment failure before it occurs, simulating process changes without disrupting production, and maintaining regulatory documentation that updates itself in near real-time.^[2] This review paper systematically examines how digital twin technology can enhance pharmaceutical PLM across its key stages. The review is organized as follows: Section 2 presents the review methodology. Section 3 covers the relevant literature. Section 4 defines conceptual foundations. Section 5 analyses stage-wise applications. Section 6 addresses regulatory dimensions. Section 7 explores implementation challenges. Section 8 discusses findings, and Section 9 concludes with recommendations.

Review Methodology

This paper adopts a narrative systematic review approach, synthesizing published research, regulatory guidance documents, and documented industry case studies relevant to digital twin technology and pharmaceutical product life cycle management. Literature was identified through searches of Google Scholar, PubMed, Science Direct, and IEEE Xplore databases using the following search terms: "digital twin pharmaceutical," "digital twin PLM," "pharmaceutical Industry 4.0," "virtual process model drug manufacturing," and "model-informed drug development." Publications from 2002 to 2024 were considered, with emphasis on peer-reviewed articles published after 2017, when the maturity of enabling technologies accelerated significantly.^[3] Inclusion criteria required that sources address digital twin technology, pharmaceutical or life sciences applications, and product life cycle dimensions explicitly. Regulatory guidance documents from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) were included as primary regulatory sources. A total of eleven principal sources were identified as directly informing the review's core arguments and are cited accordingly throughout the text.

Literature Review

Scholarship on digital twin technology has grown substantially since Grieves (2002) first introduced the concept of a "mirrored space model" within a PLM context, later refined into the term "digital twin" by NASA in the context of aircraft simulation.^[1] The initial applications were heavily concentrated in aerospace and automotive sectors, where simulation fidelity translated directly into safety and cost outcomes. Within the pharmaceutical domain, early enthusiasm was measured. Regulatory conservatism and the high stakes of product quality created a degree of institutional caution around adopting nascent simulation technologies. However, the emergence of Industry 4.0 frameworks and the growing sophistication of Internet of Things (IoT) sensors, machine learning algorithms, and cloud computing infrastructure began shifting that calculus significantly around 2016–2018.^[9][10] Musulin et al. (2021) provided one of the more comprehensive treatments of digital twins in pharmaceutical manufacturing, noting that process analytical technology (PAT) initiatives already underway in many facilities created a natural substrate for digital twin deployment.^[3] Their work illustrated how continuous monitoring data, when funneled into a validated virtual process model, could dramatically compress the time required to investigate and resolve quality deviations. Peng et al. (2020) examined digital twin applications specifically within the drug development pipeline, arguing that in-silico modeling of drug behavior — if treated as a living digital twin rather than a static computational model — could reduce late-stage clinical failures by improving early-stage predictions of efficacy and toxicity.^[4] This work opened an important conceptual bridge between computational pharmacology and operational PLM. The cold chain literature has separately developed around real-time monitoring technologies. Thakkar and Shah (2022) noted the gap in explicit integration of cold chain management within a PLM digital twin framework, proposing conceptual architectures in which temperature-sensitive biologic products could be tracked through a unified digital twin environment spanning manufacturing, warehousing, and last-mile distribution.^[5] The FDA's Pharmaceutical Quality for the 21st Century initiative and its embrace of model-informed drug development (MIDD) frameworks has created regulatory receptivity to simulation-based evidence.^[6] The EMA has likewise signaled openness to in-silico clinical trials under specific validation conditions.^[8]

Conceptual Framework

Product Life Cycle Management in Pharmaceuticals

Product Life Cycle Management, in the pharmaceutical context, encompasses the systematic management of a drug or medical product through every phase of its existence: discovery and pre-clinical research, formulation and development, clinical trials, regulatory approval, commercial launch, post-market surveillance, and eventual product withdrawal or patent expiry transition. Unlike consumer goods PLM, pharmaceutical PLM is deeply embedded in regulatory obligation — every decision, change, or deviation must be documented, justified, and in many cases pre-approved by regulatory authorities.^[11] The core objectives of pharmaceutical PLM are to reduce time-to-market, maintain product quality and safety throughout the commercial lifecycle, ensure regulatory compliance across jurisdictions, and ultimately maximize the therapeutic and commercial value of a product portfolio. These objectives are frequently in tension: speed pressures can create quality risks, and regulatory requirements can slow adaptation to evolving scientific evidence.

Digital Twin Technology: Definition and Architecture

A digital twin, as applied in this review, refers to a dynamic, bidirectionally connected virtual representation of a physical product, process, or system, continuously updated through real-time data feeds to reflect the current state of its physical counterpart.^[9] Three components are generally recognized as constitutive: the physical entity itself, the virtual model, and the data connection that links them.^[10] In pharmaceutical manufacturing, the physical entity might be a granulation unit, a tablet press, a bioreactor, or an entire production line. The virtual model captures its operational parameters — temperature profiles, pressure differentials, ingredient ratios, machine vibration signatures — in a mathematical and computational representation. The data connection, typically realized through IoT sensors and industrial communication protocols, ensures that the virtual model remains synchronized with the physical reality rather than representing a historical snapshot.^[3] What distinguishes a digital twin from a conventional simulation model is precisely this living, bidirectional character. Static simulations are run at a point in time to answer specific questions. Digital twins run continuously, accumulate operational history, and can generate predictive outputs that static models cannot provide.^[1][2]

Applications of Digital Twins Across the Pharmaceutical Product Life Cycle

Drug Discovery and Formulation Development

At the earliest stages of pharmaceutical PLM, digital twins are manifesting primarily as computational models of drug molecules and their interactions with biological targets.^[4] In-silico trials — virtual clinical studies that simulate drug behavior in modeled patient populations — represent an emerging application that regulatory bodies are beginning to evaluate seriously.^[8] For formulation development, digital twins of granulation, milling, or blending processes allow formulators to test how changes in excipient ratios or processing parameters will affect final dosage form characteristics, without consuming costly active pharmaceutical ingredients or production time.^[3] The practical impact at this stage is a compression of the iterative development cycle. Experimental runs that once required weeks of physical trials can be partially replaced or guided by virtual experimentation, with physical confirmation runs reserved for the most promising parameter spaces identified by the model. Several major pharmaceutical companies have publicly reported integration of process modeling tools in their development workflows that align closely with the digital twin paradigm.^[6]

Clinical Trial Management

Clinical trials represent perhaps the most financially consequential stage of pharmaceutical PLM. Digital twin approaches are being applied here in two related ways: patient-level modeling and operational trial management.^[4] Patient-level digital twins — virtual physiological models calibrated to individual patient characteristics — have been proposed as tools for patient stratification, dosage optimization, and adverse event prediction.^[8] While this application remains largely in research and pilot stages, its implications for trial design are significant: a more predictive understanding of how specific patient subgroups will respond could reduce sample size requirements and improve the precision of efficacy signals. At the operational level, digital twins of clinical supply chains — tracking investigational medicinal products from manufacturing through distribution to clinical sites — improve visibility into temperature excursions, delivery delays, and expiry management, all of which are frequent sources of trial disruption and regulatory audit findings.^[5]

Commercial Manufacturing and Quality Assurance

This is the domain where pharmaceutical digital twins have seen their most mature and commercially validated deployment to date.^[3] Continuous manufacturing lines generate the high-frequency, multi-parameter data streams that feed digital twin models most effectively. A digital twin of a continuous oral solid dosage manufacturing line can monitor blend uniformity, tablet weight variation, coating thickness, and dissolution profile in real time, comparing observed values against modeled predictions and flagging deviations before they propagate into finished product non-conformance. The regulatory alignment here is noteworthy. The FDA's Process Analytical Technology (PAT) guidance and the ICH's Q8, Q9, and Q10 guidelines collectively create a regulatory environment that is conceptually compatible with, and in some interpretations actively encouraging of, digital twin-based process control.^[7][11] Predictive maintenance is another manufacturing-stage benefit. Rather than scheduling equipment maintenance on fixed calendar intervals, digital twins of manufacturing equipment can analyze vibration patterns, motor current signatures, and lubrication data to predict when specific components are approaching failure, allowing maintenance to be scheduled precisely when needed and before costly unplanned downtime occurs.^[9]

Supply Chain and Cold Chain Integrity

Temperature-sensitive pharmaceutical products — biologics, vaccines, certain oncology agents — require cold chain management of extraordinary precision.^[5] A temperature excursion of even a few degrees for a short duration can degrade product potency in ways that are not visually apparent but are clinically significant. Traditional cold chain monitoring has relied on discrete data loggers placed in shipments, generating records that are reviewed after the fact. A digital twin of the cold chain integrates real-time temperature data from multiple points — storage facilities, transport vehicles, distribution hubs, and dispensing points — into a continuous model that can predict temperature excursion risk before it occurs.^[5] If a refrigeration unit at a distribution center shows early signs of thermal drift, the digital twin model can calculate the projected time to breach a critical threshold and trigger preemptive action — moving products to an alternative unit or expediting delivery — before product quality is compromised. The COVID-19 pandemic, which required global distribution of temperature-sensitive mRNA vaccines at speeds and scales without historical precedent, forcefully demonstrated both the fragility of conventional cold chain monitoring and the potential value of more predictive, integrated approaches.^[10]

Post-Market Surveillance and Product Retirement

Once a pharmaceutical product reaches the market, PLM obligations do not diminish — they evolve. Pharmacovigilance requirements mandate the collection, analysis, and regulatory reporting of adverse event data from the real-world patient population.^[6] Digital twins can serve as integrating frameworks for this post-market evidence base, connecting real-world outcomes data to the product's modeledbehavior and updating predictive risk profiles as new information accumulates.^[8] At the end of a product's commercial life — whether due to patent expiry, generic competition, reformulation, or safety withdrawal — digital twin records provide a comprehensive, traceable history of the product's performance across its entire life cycle. This history has practical value for regulatory submissions related to biosimilar development, reformulation filings, and post-approval change management.^[11]

Regulatory Implications and Compliance

Regulatory compliance is not a peripheral concern in pharmaceutical PLM — it is the organizing logic around which all other activities are structured. The adoption of digital twin technology therefore requires careful attention to how regulators interpret and evaluate simulation-based systems. The FDA's Model-Informed Drug Development (MIDD) framework, introduced formally in 2017, represents the most significant regulatory signal that quantitative modeling and simulation — the intellectual core of digital twin technology — can constitute valid evidence in regulatory submissions.^[6] The MIDD framework creates the conceptual space within which digital twin-generated evidence can be positioned in regulatory interactions. Validation remains the central regulatory requirement for any computerized system used in pharmaceutical quality decisions. 21 CFR Part 11 in the United States and Annex 11 of the EU GMP guidelines set out requirements for electronic records and computerized systems that digital twin platforms must satisfy.^[7] Data integrity is a related regulatory concern of particular relevance to digital twins. The Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA) principles that govern pharmaceutical data must extend to digital twin data pipelines.^[7][11] Organizations must be able to demonstrate that the data feeding their virtual models is authentic, unaltered, and traceable to its source.

Implementation Challenges

Notwithstanding the considerable promise of digital twin technology, its implementation in pharmaceutical PLM is not without significant obstacles operating at technical, organizational, regulatory, and economic levels. From a technical standpoint, the development of sufficiently accurate virtual models for complex pharmaceutical processes is a substantial undertaking. Pharmaceutical processes involve nonlinear interactions among multiple variables — particle size distributions, moisture content, mixing dynamics, temperature gradients — that are inherently difficult to model with the precision that quality decisions require.^[3] Model fidelity must be validated rigorously, and models must be updated as processes evolve, creating an ongoing maintenance obligation. Data infrastructure presents a parallel challenge. Many pharmaceutical manufacturing facilities, particularly those built before the widespread adoption of digital instrumentation, do not have the sensor density or data communications architecture required to feed a real-time digital twin.^[9] Retrofitting legacy facilities with the necessary IoT infrastructure involves capital expenditure, operational disruption, and potential impact on existing validated states. Organizational culture is a factor that is sometimes underestimated. Digital twin platforms generate large volumes of predictive alerts and analytical outputs that require skilled interpretation.^[10] If the workforce responsible for acting on these outputs lacks the data literacy and change-management orientation to trust and effectively use model-generated insights, the technology's potential will not be realized regardless of its technical sophistication. Finally, the economic case for digital twin investment, while generally favorable over a multi-year horizon, requires upfront capital that smaller pharmaceutical companies and generic manufacturers may find difficult to justify. Early adoption advantages tend to favor large multinational organizations, potentially widening the capability gap between large and small players.^[4]

DISCUSSION

The evidence reviewed in this paper supports a view of digital twin technology as a genuinely transformative capability for pharmaceutical PLM — one that addresses longstanding weaknesses in how the industry manages product quality, regulatory compliance, and supply chain integrity across the full product life cycle.^[1][2] A measured assessment would suggest that digital twin technology in pharmaceutical PLM is past the stage of theoretical promise and entering a phase of demonstrated value for specific applications — continuous manufacturing process control, predictive maintenance, and cold chain integrity being the clearest current examples^[3][5] — while other applications, such as patient-level digital twins and fully integrated enterprise PLM twin ecosystems, remain developmental.^[8] The regulatory trajectory is encouraging. As agencies accumulate experience with model-based submissions and develop clearer guidance on validation requirements for digital twin systems, the regulatory risk associated with adoption will diminish.^[6][7] Organizations that invest in proactive regulatory engagement are likely to develop both practical experience and regulatory relationships that will prove advantageous as the field matures. The workforce dimension deserves particular emphasis. Technology does not implement itself, and the most sophisticated digital twin platform will deliver little value if the people responsible for operating and interpreting it lack adequate training and institutional support. Pharmaceutical companies that treat digital twin adoption as a technology project rather than an organizational transformation project are likely to underperform against those that invest proportionally in human capability development alongside technical infrastructure.^[10].

CONCLUSION

This review paper has examined the role of digital twin technology in enhancing product life cycle management within the pharmaceutical industry, traversing the stages from drug discovery and formulation through commercial manufacturing, supply chain management, and post-market surveillance. The review demonstrates that digital twins offer meaningful, evidence-supported value at each of these stages, though the maturity of available applications varies and implementation requires sustained commitment of both financial and organizational resources. Three conclusions emerge with particular clarity from this review. First, the integration of digital twins within pharmaceutical PLM is not primarily a question of technical feasibility — the enabling technologies exist and are already deployed in leading organizations but rather a question of strategic prioritization and organizational readiness. Second, regulatory alignment is trending in a direction favorable to digital twin adoption, and proactive engagement with regulatory agencies can accelerate that alignment for individual organizations. Third, the benefits of digital twin-enhanced PLM — reduced development timelines, improved manufacturing consistency, enhanced cold chain reliability, more responsive post-market surveillance — are not merely operational efficiencies but patient safety imperatives. As the pharmaceutical industry continues to confront the dual pressures of scientific complexity and regulatory accountability, digital twin technology represents a credible and increasingly well-evidenced path toward PLM systems that are genuinely equal to those demands.

CONFLICT OF INTEREST

The authors have no conflicts of interest.

REFERENCES

1. Grieves, M. W. (2002). Conceptual ideal for PLM. Presentation at the Society of Manufacturing Engineers Management Forum. Troy, MI.
2. Grieves, M., & Vickers, J. (2017). Digital twin: Mitigating unpredictable, undesirable emergent behavior in complex systems. In F. J. Kahlen, S. Flumerfelt, & A. Alves (Eds.), Transdisciplinary perspectives on complex systems (pp. 85–113). Springer.
3. Musulin, E., Wohlgemuth, R., Bañares-Alcántara, R., & Woodley, J. M. (2021). Industry 4.0: A defining framework for the digitalization of pharmaceutical manufacturing. Computers & Chemical Engineering, 149, 107285.
4. Peng, G. C. Y., Alber, M., BuganzaTepole, A., et al. (2020). Multiscale modeling meets machine learning: What can we learn? Archives of Computational Methods in Engineering, 28(3), 1017–1037.
5. Thakkar, N., & Shah, N. (2022). Digital twin applications in pharmaceutical cold chain management: A conceptual framework. Journal of Pharmaceutical Sciences, 111(8), 2174–2183.
6. U.S. Food and Drug Administration. (2017). Model-Informed Drug Development: Qualifying new approaches for model-informed drug development tools. FDA Guidance for Industry. https://www.fda.gov.